Compare Global X NASDAQ 100 Covered Call ETF (QYLD) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X NASDAQ 100 Covered Call ETF vs Twist Bioscience Corp — how do they compare? Global X NASDAQ 100 Covered Call ETF trades at $18.35, while Twist Bioscience Corp trades at $125.52 (market cap $8.26B). The key difference: Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals.
| QYLD | TWST | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $18.52 | $153.10 |
52-Week Low | $16.70 | $24.16 |
Market Cap | — | $8.26B |
Enterprise Value | — | $8.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QYLD trades at $18.37, up 0.05% with a bullish technical signal from moving averages. The ETF generates income through covered calls on the NASDAQ-100, providing an estimated 11-12% yield but limiting upside participation in strong bull markets. Recent dividend payments of $0.18-$0.19 per share demonstrate consistent income generation while the underlying index experiences volatility.
The outlook remains mixed - QYLD offers attractive monthly income for retirees but has historically underperformed the NASDAQ-100 during sustained rallies. Principal erosion risk exists as the strategy caps gains during market advances. Investors should weigh high yield against potential long-term capital appreciation sacrifice in tech-heavy markets.
Twist Bioscience (TWST) trades at $128.06, up 2.68% with a bearish technical signal despite recent AI-driven momentum. The company shows strong revenue growth (2025: $377M, 2026: $432M projected) but continues to report significant losses with negative net margins. Recent news highlights AI partnerships and a $300M stock offering, while analyst consensus remains predominantly bullish with 78.6% buy ratings.
TWST presents a high-risk growth opportunity with accelerating revenue but persistent profitability challenges. The stock's valuation appears stretched at P/S of 18.09, requiring successful execution on AI initiatives and path to EBITDA breakeven. Key risks include cash burn, competitive pressures, and dependence on emerging AI-driven drug discovery markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
